Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

Completed

• Conditions: Hereditary Haemorrhagic Telangiectasia; Liver Transplant

• Registration Number: NCT03942315
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-01
• Primary Completion: 2018-02-01
• Study Completion: 2018-12-01
• Status Verified: 2019-05
• Study First Submitted: 2019-05-02
• Study First Submitted QC: 2019-05-06
• Last Update Submitted: 2019-05-06
• Study First Posted: 2019-05-08
• Last Update Posted: 2019-05-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Hereditary Hemorrhagic Telangiectasia (HHT) patient who underwent liver transplant for HHT

Exclusion Criteria

• Patient who died in the year following transplantation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in graft status after liver transplant for Hereditary Haemorrhagic Telangiectasia (HHT) (risk of recurrence)	Every 6 months after transplantation up to 5 years	Recurrent clinical examinations (including laboratory, histological and radiological investigations)